Peripheral Zone Tumor Cell Isolation via Molecular Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are ineffective in preventing the recurrence of tumor growth after surgery and standard chemotherapy/radiation therapy, as they primarily target tumor cells in the center rather than those in the peripheral zone, which have distinct characteristics and are more likely to remain post-resection.
Innovation Solution
A method to identify and isolate tumor cells from the peripheral zone surrounding a tumor center, characterized by specific molecular markers such as CD133, CD87, VEGFR-2, and PDGFR-B, and use these cells to develop novel therapeutic compounds and diagnostics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy and radiation therapy are used to treat tumor cells, then tumor growth can be temporarily controlled, but tumor recurrence occurs because peripheral zone tumor cells are not effectively targeted
Solution Approach 1:
The patent segments the tumor into distinct zones (central zone and peripheral zone) and identifies that each zone contains tumor cells with different characteristics. By specifically targeting peripheral zone cells with unique markers like CD133, CD87, VEGFR-2, and PDGFR-B, the treatment addresses the heterogeneity within the tumor, resolving the contradiction between effective treatment and comprehensive coverage.
Solution Approach 2:
The patent applies the principle of local quality by recognizing that peripheral zone tumor cells have distinct molecular characteristics compared to central zone cells. The invention develops targeted therapies that specifically address the unique marker expression profile of peripheral zone cells, ensuring that treatment is adapted to the specific properties of each tumor region rather than applying a uniform approach.
2Ease of manufacture
If conventional treatment methods target all tumor cells uniformly, then the treatment process is simple, but it fails to account for the distinct characteristics of peripheral zone cells leading to recurrence
Solution Approach 1:
The patent changes the parameters used to characterize and select tumor cells by identifying specific molecular markers (CD133, CD87, VEGFR-2, PDGFR-B) that distinguish peripheral zone cells from central zone cells. This parameter-based differentiation enables precise identification and targeting of the problematic cell population without requiring overly complex treatment protocols.
Solution Approach 2:
The patent replaces uniform mechanical/chemical treatment approaches with a more precise system based on molecular marker detection and targeted therapy. By substituting the blanket treatment approach with marker-guided selective treatment, the invention achieves both precision in cell characterization and maintainability of treatment feasibility.
3Quantity of substance
If tumor cells are removed by surgery, then the primary tumor mass is reduced, but residual peripheral zone cells remain and cause secondary tumor growth
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing peripheral zone tumor cells with specific molecular markers before they can cause recurrence. By establishing the unique marker profile of these cells in advance, the invention enables subsequent targeted therapies to eliminate residual cells that would otherwise survive standard treatment and cause secondary tumor growth.
Solution Approach 2:
The patent uses molecular markers (CD133, CD87, VEGFR-2, PDGFR-B) as intermediaries to identify and target peripheral zone tumor cells. These markers serve as mediators that link the surgical removal of visible tumor mass with the subsequent elimination of residual microscopic disease, bridging the gap between macroscopic resection and microscopic disease control.
Data Source
AI summary
The present invention relates to a tumor cell of the peripheral zone of a tumor and methods of providing such a tumor cell. Further provided is a method for identifying a molecular marker diagnostic for an infiltrative cancer, an antibody, which specifically binds to such molecular marker, a method for identifying a therapeutic compound effective against a metastatic/infiltrative cancer disease and the use of a tumor cell according to the invention.